Key facts about our TSE research
The MRC is supporting research to increase understanding of transmissible spongiform encephalopathy (TSE) disease in humans (CJD - Creutzfeldt-Jakob disease) and to develop ways of treating this rare but currently fatal condition.
What we spend on TSE research
Since the late 1970s, the MRC has funded research into all aspects of TSE disease that relate to human health, from basic biological studies to applied clinical research, epidemiology and risk assessment. In 2008/09, we spent around £8.9 million in this area.
Our research
Two key goals are the development of a reliable diagnostic test to identify the earliest possible stage of infection and to develop new treatments and preventive measures. We continue to welcome innovative research proposals in all other areas of TSE research relevant to human disease.
In 2005 the UK TSE Research and Development Joint Funders’ Co-ordination Group (Department of Health, Department for Environment, Food and Rural Affairs, Food Standards Agency, Biotechnology and Biological Sciences Research Council and the Medical Research Council) published their first joint human and animal health TSE research strategy. A supplement that updates the key features of the 2005-2008 strategy document for 2009-2011 has now been published.
A report from Professor Ian Bone, Intraventricular Pentosan Polysulphate in Human prion disease. A study of experience in the United Kingdom (lay summary), discusses PPS as a possible treatment for vCJD and related prion disorders.
Where the research takes place
The MRC funds TSE research groups in universities and hospitals throughout the UK. In addition, the MRC has a unit that focuses principally on TSE research – the MRC Prion Unit, University College London. Set up in 1998 to create an international centre of excellence, the unit provides a crucial role in bridging the interface between basic science and clinical research.
Contact: Dr Catherine Moody
Email: catherine.moody@headoffice.mrc.ac.uk